Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Beats Estimates By $0.16 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping the consensus estimate of ($4.04) by $0.16, FiscalAI reports. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.55%. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $8.13 earnings per share.

Here are the key takeaways from Jazz Pharmaceuticals’ conference call:

• Positive Sentiment: Jazz reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised 2026 revenue guidance to $4.775 billion–$4.85 billion. The company cited broad commercial execution across sleep, oncology and international markets while keeping operating-expense guidance unchanged.
• Positive Sentiment: Ziihera’s launch in first-line HER2-positive metastatic gastroesophageal adenocarcinoma generated $21 million in third-quarter sales and showed strong early community adoption, including a threefold increase in new ordering accounts in September. Jazz estimates a 3,000–4,000-patient annual U.S. addressable population and increased Ziihera’s peak-sales potential to $3 billion–$5 billion.
• Positive Sentiment: Xywav sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Management said high-sodium oxybate generics have had limited impact so far and expects Xywav’s low-sodium profile and clinical differentiation to support continued durability into 2027.
• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a precision epilepsy therapy targeting KCNT1 mutations. Initial patient efficacy data are expected this quarter, while the company also advanced its orexin-2 agonist JZP269 into a Phase I trial.
• Negative Sentiment: Zepzelca faces a likely competitive headwind in 2027 from Amgen’s IMDELLTRA following strong first-line maintenance small-cell lung cancer data, although management expects no impact to 2026 guidance. Modeyso revenue growth may also proceed at a more measured pace as Jazz expands from academic centers into community oncology ahead of the ACTION trial readout in the first half of 2027.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $1.96 on Wednesday, reaching $231.70. 248,420 shares of the company traded hands, compared to its average volume of 931,500. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The company has a 50 day moving average of $230.67 and a 200 day moving average of $216.80. The firm has a market capitalization of $15.04 billion, a PE ratio of 78.73, a PEG ratio of 0.43 and a beta of 0.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on JAZZ shares. Stifel Nicolaus set a $275.00 target price on Jazz Pharmaceuticals in a research note on Tuesday, August 4th. The Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a research report on Thursday, September 24th. They set a “buy” rating and a $337.00 price target for the company. Barclays lifted their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday. Royal Bank Of Canada boosted their price objective on Jazz Pharmaceuticals from $296.00 to $305.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $293.45.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Q3 results and outlook beat expectations. Revenue rose 10% year over year to about $1.24 billion, ahead of estimates, and the adjusted loss per share was narrower than expected. Jazz lifted its 2026 revenue guidance to roughly $4.78 billion–$4.85 billion, above consensus. Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
• Positive Sentiment: $500 million share buyback announced. The repurchase plan could support demand for shares and signals the company is allocating capital to shareholder returns. Jazz Pharmaceuticals announces a $500 million equity buyback
• Positive Sentiment: Analysts raised their targets. JPMorgan, Morgan Stanley, RBC and Barclays each increased their price targets while maintaining positive ratings, reflecting confidence in the outlook. Analysts offer insights on Jazz Pharmaceuticals
• Neutral Sentiment: Growth opportunities and risks remain. The Ziihera launch and growth in Xywav are positives, while coverage also flagged slowing growth and an Actio-related charge as factors that could weigh on investor sentiment. Jazz beats estimates, but slowing growth and an Actio charge raise questions
• Negative Sentiment: The company reported a quarterly loss. Although the adjusted loss beat forecasts, it contrasts with earnings in the year-ago quarter and may draw attention to profitability and the impact of charges. Jazz reports Q3 loss, tops revenue estimates

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total value of $1,381,980.00. Following the transaction, the director owned 345,875 shares in the company, valued at approximately $79,665,388.75. This represents a 1.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total value of $19,207,173.70. Following the completion of the transaction, the executive vice president owned 65,686 shares in the company, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 94,121 shares of company stock worth $23,337,922. Company insiders own 4.10% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.